Overview

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Status:
Recruiting
Trial end date:
2021-12-06
Target enrollment:
Participant gender:
Summary
A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
BioXcel Therapeutics Inc
Collaborator:
IQVIA Biotech